Trends in racial and ethnic disparities in pediatric lung transplantation in the United States

Abstract

AbstractBackgroundRacial and ethnic disparities in pediatric lung transplantation (LTx) related to the shifting cystic fibrosis (CF) population receiving highly effective modulator therapy (HEMT) has not been well investigated.MethodsThe UNOS Registry was queried for patients age 1–25 years undergoing bilateral LTx between 1 January 2012 and 31 December 2021. Race and ethnicity were classified as non‐Hispanic White, non‐Hispanic Black, Hispanic, or none of the above. The primary outcome was posttransplant mortality. Trends in the association between race/ethnicity and mortality were examined using transplant year as a continuous variable and stratifying year based on introduction of HEMT (triple combination therapy) in November 2019.ResultsIn the study sample (N = 941), 7% of patients were non‐Hispanic Black, 15% were Hispanic, and 2% were some other racial or ethnic group. One hundred (11%) received LTx after approval of triple combination therapy, and 407 (43%) died during follow‐up. We identified a statistically significant disparity in mortality hazard (hazard ratio: 1.91; 95% confidence interval: 1.31, 2.80) in non‐Hispanic Black compared to non‐Hispanic White patients in the pre‐triple combination therapy era.ConclusionsWe found higher mortality hazard among non‐Hispanic Black compared to non‐Hispanic White children undergoing LTx in the United States. Further monitoring of LTx outcomes to identify and address disparities is needed in the current era of triple combination therapy for CF.